Spotlight on gefitinib in non-small-cell lung cancer

American Journal of PharmacoGenomics

Volumn 5, Issue 2, 2005, Pages 133-136

  Frampton, James E ^a   Easthope, Stephanie E ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB;

CANCER SURVIVAL; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG NON SMALL CELL CANCER; PHARMACOGENOMICS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SKIN DEFECT; TREATMENT FAILURE; TREATMENT INDICATION;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 17844365052     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200505020-00006     Document Type: Review

References (32)

1. Ranson M, Wardell S. Gefitinib, a novel, orally administered agent for the treatment of cancer. J Clin Pharm Ther 2004; 29: 95-103
2. El-Reyes BF, LoRusso PM. Targetting the epidermal growth factor receptor. Br J Cancer 2004; 91: 418-24
3. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001 Sep 15; 19 (18 Suppl.): 32S-40S
4. Culy CR, Faulds D. Gefitinib. Drugs 2002; 62 (15): 2237-48
5. AstraZeneca. IRESSATM. International prescribing information, Macclesfield, Cheshire, England. 2004 Jan 15
6. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002 May 1; 20 (9): 2240-50
7. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003 Jun 15; 21 (12): 2237-46
8. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003 Oct 22; 290 (16): 2149-58
9. Gatzemeier U, Douillard JY, Kris M, et al. Rapid and durable objective responses in patients with advanced non-small-cell lung cancer in phase II trials (IDEAL 1 and IDEAL 2) treated with gefitinib [abstract no. 52]. EJC Supplements 2003 Sep; 1 (5): 20
10. Natale RB, Skarin A, Maddox A-M, et al. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. 38th Proc Am Soc Clin Oncol 2002 May; 21 (Pt 1 of 2): 292 plus poster presented at the 38th Annual Meeting of the American Society of Clinical Oncology; May 18-21, 2002; Orl
11. Herbst R, Natale R, Giaccone G, et al. ZD1839 improves disease-related symptoms and quality of life of patients with locally advanced or metastatic non-small-cell lung cancer in two randomized, double-blind studies (IDEAL-1 and IDEAL-2) [abstract no. P367]. 2002 Oct; 122 Suppl.: 166 plus poster presented at the 68th Annual International Scientific Assembley of the American College of Chest Physicians; 2002 Nov 2-
12. Douillard JY, Cella D, Natale RB, et al. Clinically meaningful improvement in disease-related symptoms by gefitinib (Iressa, ZD1839) in patients with advanced non-small-cell lung cancer: relationship between lung cancer subscale scores and radiographic response and survival. EJC Supplements 2003 Sep; 1 (5): 276-7
13. Ochs J, Grous JJ, Warner KL, et al. Final survival and safety results for 21,064 non-small-cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a US expanded access program (EAP) [abstract no. 7060]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5; New Orleans: 628
14. Cappuzzo F, Bartolini S, Ceresoli GL, et al. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br J Cancer 2004 Jan 12; 90 (1): 82-6
15. Santoro A, Cavina R, Latteri F, et al. Activity of a specific inhibitor, gefitinib (Iressa TM, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. Ann Oncol 2004 Jan; 15 (1): 33-7
16. Haringhuizen A, van Tinteren H, Vaessen HFR, et al. Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. Ann Oncol 2004 May; 15 (5): 786-92
17. Spaeth D, Deplanque G, Favrot N, et al. Gefitinib in heavily pretreated non small cell lung cancer: results of the expanded access program in Eastern France [abstract no. 7323]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5; New Orleans: 693
18. Parton M, Maisey N, Banerjee S, et al. Gefitinib in patients with non-small-cell lung cancer (NSCLC): The Royal Marsden Experience [abstract no. 7099]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5; New Orleans: 638
19. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004; 22: 785-94
20. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004; 22: 777-84
21. West H, Franklin WA, Gumerlock PH. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group Study (SWOG) S0126 [abstract no. 7014], 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5; New Orleans: 618
22. Argiris A, Mittal N. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer 2004; 43: 317-22
23. Kommareddy A, Coplin M, Gao F, et al. Single-agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer; Washington University experience. Lung Cancer 2004 Aug; 45 (2): 221-5
24. Forsythe B, Faulkner K. Safety and tolerability of gefitinib in advanced NSCLC: overview of clinical experience [abstract no. P327]. Eur Respir J 2003 Sep; 22 (Suppl. 45): 32s plus poster presented at the European Respiratory Society 13th Annual Congress, Vienna, Austria, Sept 27-Oct
25. Belani CP. ASCO conference highlights: EGFR mutations take centre stage. Signal 2004; 5 (2): 18-22
26. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004 Jun 4; 304: 1497-500
27. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med 2004; 350 (21): 2129-39
28. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004 Mar 15; 22 (6): 1103-9
29. Herbst R. Targeting the epidermal growth factor receptor: prognostic and clinical implications. EJC Supplements 2003; 1 (8): 9-15
30. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004; 96 (15): 1133-41
31. Pao W, Miller VA, Venkatraman E, et al. Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt? J Natl Cancer Inst 2004; 96 (15): 1117-9
32. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004 Aug 20; 305 (5687): 1163-7